Why Exelixis Shares Tumbled

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of drugmaker Exelixis (Nasdaq: EXEL  ) dove 13% after it announced plans to raise new capital through debt and stock offerings.

So what: Shareholders never like to see their stock diluted, so the negative reaction shouldn’t be surprising. The development-stage biotech hopes to sell 20-million new shares, and raise $225 million in convertible debt, because it's still unprofitable and needs to fund future research. At a market cap of just $720 million, the offering dilutes share value by more than 10%, so the drop in share price looks warranted. Over the last week, shares have fallen about 25%, as the company reported a sharp decline in quarterly earnings due to transferring development activities on certain drugs to Sanofi.

Now what: As a young biotech, this stock is essentially binary, with its outcome riding on the results of its cabozantinib drug, now entering Phase 3 testing. The drug is used to reduce tumor growth in cancers of the liver, kidney, and ovaries.  Considering the potential returns if the drug is successful, today’s movement is essentially noise. Investors should keep up an eye on cabozantinib’s Phase 3 trials for a better idea of where the stock is going. Initial Phase 3 trials have shown positive results.

Need another prescription for Exelixis? Get all the news you need by adding it to your watchlist.

Fool contributor Jeremy Bowman holds no positions in the companies in this article. The Motley Fool owns shares of Exelixis. Motley Fool newsletter services have recommended buying shares of Exelixis. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.


Read/Post Comments (2) | Recommend This Article (11)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On August 06, 2012, at 8:13 PM, TruffelPig wrote:

    November 17 is a critical day as Cabo might gain FDA approval for medullary thyroid cancer. I think chances are pretty good. So perhaps this is a buying opportunity.

  • Report this Comment On August 07, 2012, at 10:00 PM, DNAstock wrote:

    "The drug is used to reduce tumor growth in cancers of the liver, kidney, and ovaries."

    I thought prostate was the big opportunity for this drug because of improvement in bone mets.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1974489, ~/Articles/ArticleHandler.aspx, 11/21/2014 7:29:47 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement